Application US20260109705A1 - Ocular Disorder Treatment Compounds
Summary
USPTO published patent application US20260109705A1 on April 23, 2026, covering compounds and methods for treating ocular surface disorders associated with bacterial and parasitic infections including mites (demodex), worms, protozoa, onchocerciasis, lice, scabies, nematodes, and chlamydia. The application lists ten named inventors including Ian Holmes, Yair Alster, Charles Bosworth, Omer Rafaeli, Marc Gleeson, Robert M. Burk, Mark Richard Stewart, Jonathan Dunn, Alexander James Nicholls, and Sophie Caroline Williams. CPC classifications include C07D 493/22, A61K 31/366, and A61P 27/02.
“Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and/or parasitic infections.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 226 changes logged to date.
What changed
USPTO published patent application US20260109705A1 titled 'Compounds and Methods for the Treatment of Ocular Disorders' on April 23, 2026. The application covers topical compositions demonstrating immunological, keratolytic, anti-histamine, and anti-inflammatory activities for administration to the eyelid margin or surrounding areas. Filing date was December 14, 2023.
Affected parties include pharmaceutical and biotechnology companies developing ocular surface disorder treatments, particularly those targeting bacterial or parasitic eye conditions. This published application represents prior art that may affect freedom-to-operate analyses for competing therapeutic developers in the ocular pharmaceutical space.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS
Application US20260109705A1 Kind: A1 Apr 23, 2026
Inventors
Ian HOLMES, Yair ALSTER, Charles BOSWORTH, Omer RAFAELI, Marc GLEESON, Robert M. BURK, Mark Richard STEWART, Jonathan DUNN, Alexander James NICHOLLS, Sophie Caroline WILLIAMS
Abstract
Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and/or parasitic infections. Bacterial and/or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and/or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.
CPC Classifications
C07D 493/22 A61K 31/366 A61P 27/02
Filing Date
2023-12-14
Application No.
19141025
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.